Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1584-1587, 2023.
Artículo
en Chino
| WPRIM (Pacífico Occidental)
| ID: wpr-1010010
Biblioteca responsable:
WPRO
ABSTRACT
Multiple myeloma (MM) is a common plasma cell malignancy, accounting for the second largest hematological malignancy. Proteasome inhibitors represented by bortezomib (BTZ) have been the main treatment for patients with newly diagnosed and relapsed or refractory myeloma in nearly two decades. Although BTZ has improved the prognosis of MM patients, MM remains incurable in most patients, mainly because MM cells become resistant to BTZ. This review is to better understand the mechanism of MM resistance to BTZ and explore possible new therapeutic strategies.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Células Plasmáticas
/
Pronóstico
/
Resistencia a Antineoplásicos
/
Línea Celular Tumoral
/
Inhibidores de Proteasoma
/
Bortezomib
/
Mieloma Múltiple
/
Antineoplásicos
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Artículo